Genmab A/S (NASDAQ:GMAB) Shares Purchased by Renaissance Technologies LLC

Renaissance Technologies LLC increased its holdings in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 7.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,462,459 shares of the company's stock after buying an additional 103,859 shares during the quarter. Renaissance Technologies LLC owned 0.22% of Genmab A/S worth $36,752,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in the business. DDD Partners LLC purchased a new position in Genmab A/S in the 2nd quarter worth $8,860,000. Capital International Investors lifted its holdings in shares of Genmab A/S by 7.8% during the first quarter. Capital International Investors now owns 4,373,277 shares of the company's stock worth $130,805,000 after purchasing an additional 315,355 shares during the period. First Trust Advisors LP boosted its position in Genmab A/S by 16.0% in the fourth quarter. First Trust Advisors LP now owns 1,270,095 shares of the company's stock valued at $40,440,000 after buying an additional 175,292 shares during the last quarter. Trexquant Investment LP acquired a new position in Genmab A/S in the 4th quarter worth approximately $4,875,000. Finally, Harding Loevner LP raised its position in Genmab A/S by 2.7% during the 4th quarter. Harding Loevner LP now owns 3,289,895 shares of the company's stock worth $97,569,000 after buying an additional 85,665 shares during the last quarter. 7.07% of the stock is owned by institutional investors and hedge funds.

Genmab A/S Trading Up 0.3 %

NASDAQ:GMAB traded up $0.08 during trading hours on Thursday, reaching $26.28. 180,027 shares of the company were exchanged, compared to its average volume of 568,032. The firm has a market cap of $17.38 billion, a PE ratio of 21.93, a price-to-earnings-growth ratio of 0.81 and a beta of 0.99. Genmab A/S has a twelve month low of $24.53 and a twelve month high of $37.97. The stock's 50-day moving average is $27.29 and its 200-day moving average is $28.02.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.07). The company had revenue of $779.50 million for the quarter, compared to analyst estimates of $734.60 million. Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. As a group, research analysts anticipate that Genmab A/S will post 1.27 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on GMAB. BTIG Research increased their price objective on shares of Genmab A/S from $46.00 to $47.00 and gave the stock a "buy" rating in a research note on Thursday, June 27th. Truist Financial reduced their price objective on Genmab A/S from $53.00 to $50.00 and set a "buy" rating for the company in a research note on Monday, September 9th. JPMorgan Chase & Co. restated a "neutral" rating on shares of Genmab A/S in a research note on Tuesday, August 20th. HC Wainwright reiterated a "buy" rating and set a $50.00 price target on shares of Genmab A/S in a research report on Friday, September 13th. Finally, Royal Bank of Canada upgraded Genmab A/S from a "sector perform" rating to an "outperform" rating in a research report on Monday, July 15th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average price target of $45.20.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.